Roswell Park at ASCO

Saturday, May 30, 2026

• Michael Wong, MD presenting author, Abstract 9518 - A 3-year landmark overall survival analysis of RP1 plus nivolumab in patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial.
  • 4:30 p.m.

• Mariam Haji Ahmad, MBBCh, (PGY 3 Hematology Oncology Fellow), first author, presenting - Standardized exam-style benchmarking of large language models in breast cancer clinical decision-making.
   
• Vaishali Deenadayalan, MBBS, (PGY 3 Hematology Oncology Fellow), first author, presenting abstract 1135 - Impact of protein–energy malnutrition on outcomes of metastatic triple-negative breast cancer patients receiving chemotherapy: A real-world analysis.
  • 2026 Conquer Cancer Merit Award Winner
     
• Yu Fujiwara, MD, first author, presenting Abstract 11127 - Poster Board 110 - Safety and efficacy of immunotherapy rechallenge in solid tumors after discontinuation of immune checkpoint inhibitors for immune-related adverse events: A systematic review and meta-analysis.
  • 2026 Conquer Cancer Merit Award Winner
     
• Prantesh Jain, MD, FACP, senior author, presenting Abstract TPS2678 - Poster board 461b, A phase 1b, two-arm study of tolododekin alfa (ANK-101) in combination with an anti–PD-1/PD-L1 antibody in participants with advanced non–small cell lung cancer (NSCLC).
   
• Fayaz Khan, first author, presenting - Prophylactic vs reactive PEG tube placement in early-stage head and neck (H&N) cancer treated with curative-intent radiotherapy: Balancing benefit and burden in real-world practice.
  • 2026 Conquer Cancer Merit Award Winner
     
• Fayaz Khan, first author, presenting - Pre-lymphodepletion CRP and ferritin risk stratification as a predictor of early immune toxicities and hematologic complications after CAR-T therapy: A propensity-matched cohort study.
   
• Jayasree Krishnan, MD, MSPH, (PGY 4 Hematology Oncology Fellow), first author, presenting publication 7541 - CAR-T in the older adults: Real-world survival and toxicity in patients ≥ 75 years with relapsed/refractory multiple myeloma.
  • 2026 Conquer Cancer Merit Award Winner
     
• Olivia Martin, MD, MS, first author presenting Abstract 11541 - Poster 331, with senior author Ankit Patel, MD: Cell proliferation, immune cell infiltration, and survival outcomes in sarcomas with high cancer-associated fibroblast expression,  with senior author Ankit Patel, MD.
   
• Masanori Oshi, MD, first author, presenting Abstract 576, Poster 61, ILCness to stratify lobular-like breast cancer biology and as an outcome independent of CDH1 mutation in early ER-positive/HER2-negative breast cancer, with senior author Kazuaki Takabe, MD, PhD.
   
• Mrinalini Ramesh, DO, first and presenting author, presenting Abstract 1535, Poster 259, Hospital designation and survival disparities in young-onset gastrointestinal cancer.
   
• Zunairah Shah, MBBS, first author, presenting - Real-world brain metastasis outcomes with T-DXd versus tucatinib-based therapy in second-line HER2-positive metastatic breast cancer.
  • 2026 Conquer Cancer Merit Award Winner
     
• Zunairah Shah, MBBS, first author, presenting - GLP-1 therapy and hormone receptor–positive breast cancer risk and survival: A real-world analysis.
   
• Zunairah Shah, MBBS, first author, presenting - Real-world cardiotoxicity with HER2 antibody–drug conjugates and survival after treatment continuation.
   
• Rahul Thakur, MD, first author, presenting Abstract 1558, Poster 308, Assessment of CAR-T clinical trial availability and accessibility in the United States. with senior author Ehsan Malek, MD.

Eunice Wang, MD, is the invited speaker for the educational session New Drugs in Oncology: Incorporation Into Practice.

• Friday, May 29, 2026 2:45-4:15 p.m.
• Presenting Ziftomenib and Revumenib for Relapsed or Refractory Acute Myeloid Leukemia

Thoracic surgeon Todd Demmy, MD, FACS, to be onsite at ASCO 2026 participating in the U.S. National Science Foundation’s Innovation Corps (I-Corps) program, an immersive, entrepreneurial training program that facilitates the transformation of invention to impact.